Fox Chase Cancer Center News

May 23, 2016

Pembrolizumab Effective for Patients with Advanced Head and Neck Squamous Cell Carcinoma

PHILADELPHIA (May 23, 2016) —Pembrolizumab, an anti-programmed death cell protein 1 antibody, is successful in treating advanced head and neck squamous cell carcinoma, according to researchers from Fox Chase Cancer Center-Temple Health. This provides a new treatment option with fewer side effects. Presented at ASCO 2016 Annual Meeting.

Yi Zhang, MD
May 19, 2016

New Programming Approach Produces Alloreactive T Cells That Destroy Leukemia Without Added Risk of GvHD

PHILADELPHIA (May 19, 2016) — Researchers from Fox Chase Cancer Center and Temple University have developed a cellular programming approach that creates alloreactive T cells that are able to eliminate leukemic cells without causing graft versus host disease (GvHD).

May 4, 2016

Fox Chase Urges Individuals to Protect Skin from Sun Damage All Year Round

PHILADELPHIA (May 4, 2016) — May is Skin Cancer Awareness Month, and chances are you will be spending more time outdoors. Fox Chase Cancer Center advises people to protect their skin from sun damage and become familiar with the early signs of skin cancer.

May 2, 2016

Fox Chase Cancer Center–Temple Health Supports the Bladder Cancer Advocacy Network and AMP UP

PHILADELPHIA (May 2, 2016) — Faculty, staff, volunteers, patients, survivors and their families and friends will come together as members of the Fox Chase Cancer Center–Temple Health team at AMP UP! Move to End Bladder Cancer’s annual 2-mile walk on Saturday, May 14, 2016.

Neil Johnson, PhD
May 1, 2016

Newly Discovered Cause of Drug Resistance Could Improve Outcomes for Breast and Ovarian Cancer

PHILADELPHIA (May 1, 2016) — Many patients with breast or ovarian cancer initially benefit from DNA-damaging chemotherapies, but it has not been clear why these treatments lose effectiveness over time. In a new study, Fox Chase Cancer Center researchers showed that patients with mutations affecting a specific portion of the BRCA1 gene were susceptible to a new pathway of resistance to DNA-damaging drugs, including PARP inhibitors and platinum compounds.

Susan G. Komen Philadelphia’s 26th Annual Race for the Cure, May 8, 2016
April 25, 2016

Fox Chase Cancer Center-Temple Health Support Race for the Cure

PHILADELPHIA (April 25, 2016) — Faculty, staff, volunteers, patients, survivors, and their families and friends will come together as members of the Fox Chase Cancer Center-Temple Health team at Susan G. Komen Philadelphia’s 26th Annual Race for the Cure on Mother’s Day — Sunday, May 8, 2016.

Richard I. Fisher, MD
April 22, 2016

Lymphoma Research Foundation To Host Hundreds at Philadelphia Patient Workshop

PHILADELPHIA (April 22, 2016) – Lymphoma Workshop: Understanding Lymphoma Basics and Current Treatment Options, will be on May 7, 2016, at the Sheraton Philadelphia Downtown Hotel in Philadelphia, Pennsylvania.

April 22, 2016

72 Temple Physicians Named “Top Doctors” by Philadelphia Magazine

PHILADELPHIA (April 22, 2016) Seventy-two Temple physicians have been named to Philadelphia magazine’s “Top Doctors” list for 2016. Physicians on the list were nominated by their professional peers and practice at Temple University Hospital, Fox Chase Cancer Center, Jeanes Hospital and in the community as part of Temple Physicians, Inc.